I highly doubt that - any continued dosing from Phase IIb for participants post their trial if they decide to continue it in 18-24 months time would be separated the data wouldn't be released until after completion of the trial. It would just make the trial messy it would be under a separate protocol. I'd also assume it wont be a straight continuation as with the last trial the last time point measured is 4 & 8 week post treatment.
Chart, page-1267
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.004(5.48%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.3¢ | 7.7¢ | 7.3¢ | $40.33K | 536.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 79999 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.004 ( 5.56 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.6¢ | 7.4¢ | 32400 | ||
| Last updated 14.37pm 02/05/2024 ? | |||||
| PER (ASX) Chart |